12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TNF-Kinoid: Final Phase IIa data

Final data from the double-blind, international Phase II TNF-K-005 trial in 60 patients with moderate to severe CD who have failed >=1 anti-TNF therapy showed that 3 doses of 180 µg TNF-Kinoid produced an immune response in 65% of patients with active disease (CDAI score of >150 points) and no residual anti-TNF antibodies at baseline. Additionally, a fourth dose of TNF-Kinoid given at day 84 caused a rebound in antibody titers to a peak higher than that seen after the initial 3 doses. In patients who received...

Read the full 411 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >